RxDoctor Payments Data

Justin Crawford, APRN

Family · Lugoff, SCNPI 1134606122

Payments from drug & device makers

$1,933in general payments, 2019–2025

Across 91 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$382
  • Novo Nordisk$149
  • AbbVie$147
  • Boston Scientific$139
  • Cvrx, Inc.$136
  • Medtronic$80
  • plus $900 from 23 others

What the payments were for

  • Food & beverage$1,933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,933 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$74,046
Medicare patients
296
Services billed
2,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$75,353
JardianceEmpagliflozin57$58,895
FarxigaDapagliflozin Propanediol25$32,103
EliquisApixaban44$31,531
MounjaroTirzepatide12$19,845
LinzessLinaclotide25$15,441
Repatha SureclickEvolocumab13$15,263
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,557
Breo ElliptaFluticasone/Vilanterol15$5,782
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,832
Rosuvastatin Calcium138$4,179
Gabapentin158$2,821
Atorvastatin Calcium284$2,701
Omeprazole196$2,540
Albuterol Sulfate HfaAlbuterol Sulfate113$2,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$75,35355 claims
Boehringer IngelheimJardiance$35$58,89557 claims
AstraZenecaFarxiga, Breztri Aerosphere$382$43,66039 claims
PfizerEliquis$27$31,53144 claims
Lilly USA, LLCMounjaro$38$19,84512 claims
AbbVieLinzess$147$15,44125 claims
GSKBreo Ellipta$78$5,78215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Lugoff

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →